Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

NCT06868628 is registered in ClinicalTrials.gov with Tiziana Life Sciences LTD as lead sponsor.

NCT NCT06868628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06868628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Lead sponsor
Tiziana Life Sciences LTD
Phase
Phase 2
Overall status
Recruiting
Start date
May 19, 2025
Completion date
April 1, 2027
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy